Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2015


Here are the related meetings in 2017:
Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics (A9)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Epigenetics and Cancer (A4)


Organizer(s) Tony Kouzarides and Kristian Helin
January 25—30, 2015
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Sep 30, 2014
Abstract Deadline: Oct 23, 2014
Scholarship Deadline: Sep 30, 2014
Discounted Registration Deadline: Nov 24, 2014

Sponsored by AstraZeneca, Bayer HealthCare Pharmaceuticals, Cell Research, Cell Signaling Technology, Inc., Constellation Pharmaceuticals and Incyte Corporation. Supported by an educational grant from Celgene Corporation.

Summary of Meeting:
Cancer epigenetics is a new and rapidly developing area of research. This results from the discovery that many epigenetic regulators (chromatin modifying enzymes, modification-reading proteins and chromatin-remodeling activities) are found mutated in cancers and has led to the recent approval of cancer drugs targeting epigenetic enzymes. The meeting aims to bring together scientists who are interested in understanding the connections between basic epigenetic pathways and the process of cancer. One aspect of the meeting will highlight the mechanisms by which epigenetic pathways control various biological processes. Information will be presented on chromatin and DNA modifications, chromatin complexes and ncRNAs. A second aspect will revolve around the connections between epigenetic pathways and cancer. This section will highlight genetic and epigenetic changes that take place during oncogenesis and efforts to counteract cancer with small molecule inhibitors against epigenetic regulators. The hope is to provide a forum for the interchange of information and know-how between the two converging fields of cancer research and epigenetics.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, JANUARY 25

16:00—20:00
Arrival and Registration

Longs Peak Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Longs Peak Foyer

MONDAY, JANUARY 26

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:15
Epigenetic Modifications and Cancer
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Luciano Di Croce, Centre for Genomic Regulation, Spain

Ali Shilatifard, Northwestern University, USA
Enhancer Malfunction in Cancer

Kristian Helin, University of Copenhagen, Denmark
Histone Methylation in Differentiation and Disease

Peter Verrijzer, Erasmus University Medical Center, Netherlands
Short Talk: Chromatin Remodelers in Development and Disease

Richard A. Young, Whitehead Institute for Biomedical Research, USA
Enhancer Structure and Function in Stem Cells and Cancer

Tony Kouzarides, University of Cambridge, UK
Epigenetic Modifications: Their Function and Role in Cancer

Tobias Neff, Children's Hospital Colorado, USA
Short Talk: Tumor Suppressor Functions of PRC2 in a Mouse Model of ETP-ALL

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—13:00
Poster Setup

Shavano/Torreys
13:00—22:00
Poster Viewing

Shavano/Torreys
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:15
Mechanisms of Epigenetic Signaling
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Peter Verrijzer, Erasmus University Medical Center, Netherlands

Jeannie T. Lee, Massachusetts General Hospital, USA
RNA-Protein Interactions in Epigenetic Regulation

François Fuks, Université Libre De Bruxelles, Belgium
Short Talk: New Modes of Regulation of TET Enzymes and Hydroxymethylation

Gala Filippova, University of Washington, USA
Short Talk: CTCF-Mediated Epigenetic Stability as a Barrier to Neoplastic Progression

Salvador Aznar Benitah, ICREA and Institute for Research in Biomedicine, Spain
Short Talk: Enhancer Modulation by Dnmt3a and Dnmt3b Regulates Epidermal Stem Cell Homeostasis: ImpacE on Aging and Cancer

Cigall Kadoch, Dana-Farber Cancer Institute, Harvard Medical School, USA
Short Talk: Remodeling the Remodelers: BAF Complex Structure and Function in Human Cancer

Ramin Shiekhattar, University of Miami, USA
Biogenesis and Mechanism of Action of enhancer RNAs

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Shavano/Torreys
19:30—22:00
Poster Session 1

Shavano/Torreys

TUESDAY, JANUARY 27

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:15
Components of Epigenetic Pathways
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Johnathan R. Whetstine, Massachusetts General Hospital, USA

Shelley L. Berger, University of Pennsylvania, USA
Novel Epigenetic Signatures of Wild Type and Mutant p53 Transcriptional Activity

Danny F. Reinberg, HHMI/New York University, USA
Chromatin Regulation by Polycomb Complexes

Adrian P. Bracken, Trinity College Dublin, Ireland
Short Talk: Divergent and Overlapping Functions of Polycomb–Like Proteins in the Control of Cellular Proliferation.

Luciano Di Croce, Centre for Genomic Regulation, Spain
Unveiling Polycomb Functions in Stem Cells and Cancer

Diego Pasini, European Institute of Oncology, Italy
Short Talk: Function and Mechanism of Action of the Polycomb Repressive Complex 1 in the Homeostasis of Adult Intestinal Stem Cells

Thomas Jenuwein, Max Planck Institute of Immunobiology and Epigenetics, Germany
Suv39h-Dependent H3K9me3 Represses Intact Retrotransposons in Mouse Embryonic Stem Cells

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—13:00
Poster Setup

Shavano/Torreys
13:00—22:00
Poster Viewing

Shavano/Torreys
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Epigenetic Changes in Stem Cells and Cancer
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Salvador Aznar Benitah, ICREA and Institute for Research in Biomedicine, Spain

James E. Bradner, Novartis Institutes for BioMedical Research, USA
Disruption of Super Enhancers in Cancer Therapy

Christopher Vakoc, Cold Spring Harbor Laboratory, USA
Chromatin Regulators as Cancer Dependencies

Johnathan R. Whetstine, Massachusetts General Hospital, USA
Short Talk: Understanding Copy Number Variation through Chromatin Modulation

Miguel Rivera, Massachusetts General Hospital / Harvard Medical School, USA
Short Talk: EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Induce or Repress Enhancers in Ewing Sarcoma

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Shavano/Torreys
19:30—22:00
Poster Session 2

Shavano/Torreys

WEDNESDAY, JANUARY 28

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:15
Epigenetics in Hematopoietic Tumors
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Christopher Vakoc, Cold Spring Harbor Laboratory, USA

Ross L. Levine, Memorial Sloan-Kettering Cancer Center, USA
Role of Mutations in Epigenetic Regulators in Pathogenesis of Myeloid Malignancies

Iannis Aifantis, New York University School of Medicine, USA
Cytosine Hydroxy-Methylating Enzymes in the Control of Leukemia Initiation and Progression

Toshio Kitamura, University of Tokyo, Institute of Medical Science, Japan
Short Talk: MDS Induced by ASXL1 Mutations and its Leukemic Transformation by an Additional SETBP1 Mutation

Johannes Zuber, Research Institute of Molecular Pathology, Vienna Biocenter, Austria
Comparative Analysis of Chromatin Dependencies in Leukemia Using Advanced RNAi

Mark A. Dawson, Peter MacCallum Cancer Centre, Australia
Short Talk: Targeting Epigenetic Regulators in Haematological Malignancies

Scott A. Armstrong, Dana-Farber Cancer Institute, USA
Targeting Histone Modifications and Hox Gene Expression in Leukemia

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—13:00
Poster Setup

Shavano/Torreys
13:00—22:00
Poster Viewing

Shavano/Torreys
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:15
Epigenetics Meets Genetics
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Cigall Kadoch†, Dana-Farber Cancer Institute, Harvard Medical School, USA

Peter Campbell, Wellcome Trust Sanger Institute, UK
Interrogating the Architecture of Cancer Genomes

Anjana Rao, La Jolla Institute for Allergy and Immunology, USA
TET proteins, 5-methylcytosine oxidation and cancer

Berkley Gryder, NCI, National Institutes of Health, USA
Short Talk: Genetic, Epigenetic and Molecular Sensitivity Landscape of Pediatric Rhabdomyosarcoma

Charles M. Roberts, Dana-Farber Cancer Institute, Harvard Medical School, USA
SWI/SNF Chromatin Remodeling Complexes in Cancer

Christine Fillmore Brainson, University of Kentucky, USA
Short Talk: EZH2 Inhibition Sensitizes BRG1 and EGFR Mutant lung Tumors to TopoII Inhibitors

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Shavano/Torreys
19:30—22:00
Poster Session 3

Shavano/Torreys

THURSDAY, JANUARY 29

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:15
Epigenetic Cancer Therapies I
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Mark A. Dawson, Peter MacCallum Cancer Centre, Australia

Patrick Trojer, Constellation Pharmaceuticals, USA
EZH2 Represses Interferon Signaling in Lymphoma

George P. Souroullas, University of North Carolina, USA
Short Talk: Mechanistic Understanding of the Ezh2Y641F Mutation in Lymphoma

Heike Keilhack, Epizyme, Inc, USA
EZH2 as a Target for Genetically Defined Cancers

Rab K. Prinjha, GlaxoSmithKline, UK
Short Talk: Epigenetics Drug-Discovery: From Target to Patients with BET Bromodomain Inhibitors

Christopher L. Carpenter, GlaxoSmithKline, USA
Targeting Epigenetic Pathways to Treat Cancer

Alexander Tarakhovsky, Rockefeller University, USA
Abrogation of T Cell Immunity by the Ezh2 Inactivation

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Epigenetic Cancer Therapies II
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Rab K. Prinjha, GlaxoSmithKline, UK

Stefan Knapp, University of Oxford, UK
Towards a Chemical Probe Set Targeting the Human Bromodomain Family

Daniela Kleine-Kohlbrecher, EpiTherapeutics Aps, Denmark
Short Talk: The Development of Therapeutic Inhibitors of the KDM5 Histone Demethylases

Thomas Paul, Pfizer Worldwide Research and Development, USA
Targeting SMARCA2/4 in SWI/SNF Mutant Cancers

Nicholas J. Keen, Novartis Institutes for BioMedical Research, USA
Systematic Approaches to Targeting Epigenetic Regulators in Cancer

19:00—19:30
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Grays Peak
19:30—20:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Shavano/Torreys
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Shavano/Torreys

FRIDAY, JANUARY 30

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

AstraZeneca Bayer HealthCare Pharmaceuticals

Educational grant from Celgene Corporation
Cell Signaling Technology, Inc.
Cell Research Constellation Pharmaceuticals
Incyte Corporation
 

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Abcam plc Bethyl Laboratories, Inc.
Inventiva Sigma Life Science
Zymo Research Corporation
 

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA189412-01

Funding for this conference was made possible (in part) by 1R13CA189412-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Constellation Pharmaceuticals


Epizyme, Inc.


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676